DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Sarcopenia - Market Insights, Epidemiology and Market Forecast to 2023 - 7MM" drug pipelines to their offering.
Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition.
According to research, the market size of Sarcopenia in 7MM is expected to grow at a CAGR of 2.36% for the forecast period 2013-2023. Also the prevalence cases in 7MM are expected to increase and reach up to 42,969,489 cases by year 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by our team of industry experts.
Scope of the Report:
- The report will help in developing business strategies by understanding the trends shaping and driving the Sarcopenia market.
- Organize sales and marketing efforts by identifying the best opportunities for Sarcopenia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
- To understand the future market competition in the 7MM market of Sarcopenia and Insightful review of the key market drivers and barriers.
- To understand the regulatory scenario in major markets.
The report also covers the detailed historical and forecasted
Sarcopenia market covering United States, Europe (Germany, Spain,
Italy, France and United Kingdom) and Japan from 2013-2023.
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/kc5v94/sarcopenia